Back to Search
MARC GARNICK, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1861429342IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
39022(MA)
Education
PERELMAN SCHOOL OF MED AT THE UNIVERSITY OF PENNSYLVANIA
Class of 1972
Research & Publications (15)
Important considerations in LHRH antagonist therapy for prostate cancer.
PMID 19626833·Oncology (Williston Park)·2009
8-other
Overview consensus statement. Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer.
PMID 11184767·Mol Urol·2000
6-review
Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
PMID 11062384·Mol Urol·2000
3-trial
Redefining the refined retroperitoneal lymph node dissection in testis cancer: a SWOT analysis of nonrandomized data.
PMID 17906195·J Clin Oncol·2007
8-other
Proprietary Rel-Ease drug delivery technology: opportunity for sustained delivery of peptides, proteins and small molecules.
PMID 16948561·Expert Opin Drug Deliv·2006
6-review
Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
PMID 17155895·Future Oncol·2006
6-review
Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
PMID 17001181·Anticancer Drugs·2006
3-trial
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
PMID 16813881·J Urol·2006
8-other
Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
PMID 15102870·J Clin Pharmacol·2004
3-trial
An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.
PMID 14624912·Urology·2003
3-trial
Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer.
PMID 12709720·Clin Pharmacol Ther·2003
4-observational
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.
PMID 11912385·J Urol·2002
3-trial
The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
PMID 11342922·J Urol·2001
3-trial
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
PMID 11711355·Urology·2001
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 330 BROOKLINE AVE, RM1026 BETH ISRAEL HOSPITAL
BOSTON, MA 02215 - Phone
- (617) 667-5288
Quick Facts
- NPI
- 1861429342
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 54
- Publications
- 15
Are you this provider?
Claim Your Profile